Award Year / Program / Phase:2010 / SBIR / Phase I
Agency:HHS
Principal Investigator:Graham P. Allaway
Award Amount:$180,571.00
Abstract:
DESCRIPTION (provided by applicant): The overall goals of the proposed phase 1 SBIR project are to investigate the in vivo efficacy and mechanism of action of a novel, first-in-class drug candidate for treating interstitial cystitis/painful bladder syndrom
e (IC/PBS). IC/PBS is a chronic and… More
CEL-031 is being developed as a novel, targeted tre8tment for non-mLiscle invasive bladder cancer (NMIBC). Bladder cancer is the 5th most common cancer in the US, with most cases diagnosed 8t the nonmuscle invasive stage. It is the most expensive cancerto treDt on a per patient basis. There is 8… More